10.88
0.00 (0.00%)
| Penutupan Terdahulu | 10.88 |
| Jumlah Dagangan | 516,688 |
| Harga / Jualan (P/S) | 52.50 |
| Harga / Buku (P/B) | 2.64 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -1.78 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.03% |
| Nisbah Semasa (MRQ) | 20.34 |
| Aliran Tunai Operasi (OCF TTM) | -50.76 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -33.03 M |
| Pulangan Atas Aset (ROA TTM) | -24.05% |
| Pulangan Atas Ekuiti (ROE TTM) | -34.72% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Sagimet Biosciences Inc. - Seri | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 4.0 |
| Purata | -1.17 |
|
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 13.03% |
| % Dimiliki oleh Institusi | 44.74% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Balyasny Asset Management L.P. | 30 Jun 2026 | 3,626,113 |
| Silverarc Capital Management, Llc | 30 Jun 2026 | 2,927,698 |
| Caligan Partners Lp | 30 Jun 2026 | 2,500,000 |
| Affinity Asset Advisors, Llc | 30 Jun 2026 | 2,497,864 |
| Federated Hermes, Inc. | 30 Jun 2026 | 2,086,715 |
| Great Point Partners I Lp | 30 Jun 2026 | 2,029,933 |
| Saturn V Capital Management Lp | 30 Jun 2026 | 1,479,918 |
| Blue Owl Capital Holdings Lp | 30 Jun 2026 | 1,260,544 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |